These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 35733515)
21. Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial. Gatz SA; Harttrampf AC; Brard C; Bautista F; André N; Abbou S; Rubino J; Rondof W; Deloger M; Rübsam M; Marshall LV; Hübschmann D; Nebchi S; Aerts I; Thebaud E; De Carli E; Defachelles AS; Paoletti X; Godin R; Miah K; Mortimer PGS; Vassal G; Geoerger B Clin Cancer Res; 2024 Feb; 30(4):741-753. PubMed ID: 38051741 [TBL] [Abstract][Full Text] [Related]
22. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Takebe N; Naqash AR; O'Sullivan Coyne G; Kummar S; Do K; Bruns A; Juwara L; Zlott J; Rubinstein L; Piekarz R; Sharon E; Streicher H; Mittra A; Miller SB; Ji J; Wilsker D; Kinders RJ; Parchment RE; Chen L; Chang TC; Das B; Mugundu G; Doroshow JH; Chen AP Clin Cancer Res; 2021 Jul; 27(14):3834-3844. PubMed ID: 33863809 [TBL] [Abstract][Full Text] [Related]
23. Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors. Någård M; Ah-See ML; So K; Vermunt M; Thistlethwaite F; Labots M; Roxburgh P; Ravaud A; Campone M; Valkenburg-van Iersel L; Ottesen L; Li Y; Mugundu G Cancer Chemother Pharmacol; 2020 Jul; 86(1):97-108. PubMed ID: 32556602 [TBL] [Abstract][Full Text] [Related]
24. A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. Veldhuijzen van Zanten SEM; El-Khouly FE; Jansen MHA; Bakker DP; Sanchez Aliaga E; Haasbeek CJA; Wolf NI; Zwaan CM; Vandertop WP; van Vuurden DG; Kaspers GJL J Neurooncol; 2017 Nov; 135(2):307-315. PubMed ID: 28748343 [TBL] [Abstract][Full Text] [Related]
25. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive Oza AM; Estevez-Diz M; Grischke EM; Hall M; Marmé F; Provencher D; Uyar D; Weberpals JI; Wenham RM; Laing N; Tracy M; Freshwater T; Lee MA; Liu J; Qiu J; Rose S; Rubin EH; Moore K Clin Cancer Res; 2020 Sep; 26(18):4767-4776. PubMed ID: 32611648 [TBL] [Abstract][Full Text] [Related]
26. Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study. Kato H; de Souza P; Kim SW; Lickliter JD; Naito Y; Park K; Kumar S; Mugundu GM; Bang YJ Target Oncol; 2020 Feb; 15(1):75-84. PubMed ID: 32034630 [TBL] [Abstract][Full Text] [Related]
27. Proton therapy for newly diagnosed pediatric diffuse intrinsic pontine glioma. Muroi A; Mizumoto M; Ishikawa E; Ihara S; Fukushima H; Tsurubuchi T; Sakurai H; Matsumura A Childs Nerv Syst; 2020 Mar; 36(3):507-512. PubMed ID: 31728705 [TBL] [Abstract][Full Text] [Related]
29. Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy. Gardner SL; Tarapore RS; Allen J; McGovern SL; Zaky W; Odia Y; Daghistani D; Diaz Z; Hall MD; Khatib Z; Koschmann C; Cantor E; Kurokawa R; MacDonald TJ; Aguilera D; Vitanza NA; Mueller S; Kline C; Lu G; Allen JE; Khatua S Neurooncol Adv; 2022; 4(1):vdac143. PubMed ID: 36382108 [TBL] [Abstract][Full Text] [Related]
30. Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study. Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Rekić D; Dota C; Ottesen LH; Li Y; Mugundu GM Cancer Chemother Pharmacol; 2023 Aug; 92(2):141-150. PubMed ID: 37368100 [TBL] [Abstract][Full Text] [Related]
31. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879 [TBL] [Abstract][Full Text] [Related]
32. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Chassot A; Canale S; Varlet P; Puget S; Roujeau T; Negretti L; Dhermain F; Rialland X; Raquin MA; Grill J; Dufour C J Neurooncol; 2012 Jan; 106(2):399-407. PubMed ID: 21858607 [TBL] [Abstract][Full Text] [Related]
33. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423 [TBL] [Abstract][Full Text] [Related]
34. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Janssens GO; Gandola L; Bolle S; Mandeville H; Ramos-Albiac M; van Beek K; Benghiat H; Hoeben B; Morales La Madrid A; Kortmann RD; Hargrave D; Menten J; Pecori E; Biassoni V; von Bueren AO; van Vuurden DG; Massimino M; Sturm D; Peters M; Kramm CM Eur J Cancer; 2017 Mar; 73():38-47. PubMed ID: 28161497 [TBL] [Abstract][Full Text] [Related]
35. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring Fu S; Yao S; Yuan Y; Previs RA; Elias AD; Carvajal RD; George TJ; Yuan Y; Yu L; Westin SN; Xing Y; Dumbrava EE; Karp DD; Piha-Paul SA; Tsimberidou AM; Ahnert JR; Takebe N; Lu K; Keyomarsi K; Meric-Bernstam F J Clin Oncol; 2023 Mar; 41(9):1725-1734. PubMed ID: 36469840 [TBL] [Abstract][Full Text] [Related]
36. Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. Carceller F; Fowkes LA; Khabra K; Moreno L; Saran F; Burford A; Mackay A; Jones DT; Hovestadt V; Marshall LV; Vaidya S; Mandeville H; Jerome N; Bridges LR; Laxton R; Al-Sarraj S; Pfister SM; Leach MO; Pearson AD; Jones C; Koh DM; Zacharoulis S J Neurooncol; 2016 Aug; 129(1):109-21. PubMed ID: 27180091 [TBL] [Abstract][Full Text] [Related]
37. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Cohen KJ; Heideman RL; Zhou T; Holmes EJ; Lavey RS; Bouffet E; Pollack IF Neuro Oncol; 2011 Apr; 13(4):410-6. PubMed ID: 21345842 [TBL] [Abstract][Full Text] [Related]
38. Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status. Roering P; Siddiqui A; Heuser VD; Potdar S; Mikkonen P; Oikkonen J; Li Y; Pikkusaari S; Wennerberg K; Hynninen J; Grenman S; Huhtinen K; Auranen A; Carpén O; Kaipio K Front Oncol; 2022; 12():954430. PubMed ID: 36081565 [TBL] [Abstract][Full Text] [Related]
39. Ketogenic diet treatment in diffuse intrinsic pontine glioma in children: Retrospective analysis of feasibility, safety, and survival data. Perez A; van der Louw E; Nathan J; El-Ayadi M; Golay H; Korff C; Ansari M; Catsman-Berrevoets C; von Bueren AO Cancer Rep (Hoboken); 2021 Oct; 4(5):e1383. PubMed ID: 33939330 [TBL] [Abstract][Full Text] [Related]